) recently announced its plans to launch QuantiFERON-TB Gold
In-Tube in China. The product was awarded China Food and Drug
Administration (CFDA) approval earlier this year but Qiagen has
chosen to commercially launch it on World TB Day 2014 on Mar 24.
The QuantiFERON-TB Gold In-Tube is a blood test designed to
(TB) bacterium in people (both with latent tuberculosis infection
and active tuberculosis disease).QuantiFERON-TB is being adopted
by most health care providers worldwide as it has demonstrated
itself as a faster, more precise and cost-effective method, at
the same time being user friendly. This next-generation blood
test has the capacity to steadily supplant the century-old
tuberculin skin test (TST) used in screening TB infections.
Qiagen's QuantiFERON-TB Gold In-Tube is among the five growth
drivers of the company. The product's sales rose by more than 20%
at Constant Exchange Rate (CER) in 2013 contributing to 6% of
total sales in 2013. Encouraged by the popularity of the product
in major markets like Europe and the U.S., management at Qiagen
is set to capitalize on this opportunity by expanding its
geographical presence. The product launch in China marks a step
toward the attainment of this growth strategy.
China- the world's second largest market for TB tests,
records tentatively 1 million new active TB cases per year. Per
the World Health Organization (WHO), one-third of the world's
population suffers from latent TB infection. With
urbanization on the rise in China, the incidence and spread of
this infection through transmission is only likely to increase.
Having recognized the potential that China holds in the field of
TB testing, Qiagen expects QuantiFERON-TB Gold In-Tube to witness
high adoptability in the country and meet its sales expectation
of over $100 million in 2014.
QuantiFERON-TB Gold In-Tube is also capable of providing
accurate results without being affected by the Bacille
Calmette-Guérin (BCG) vaccinationunlike TST. BCG vaccination is
mandatory for the new-born in certain countries like China. Thus,
this poses another plausible reason why the product has huge
market potential in China.
Currently, Qiagen carries a Zacks Rank #3 (Hold). Some
better-ranked stocks in the broader healthcare sector are
Alexion Pharmaceuticals, Inc.
ANI Pharmaceuticals, Inc.
). All the three stocks sport a Zacks Rank #1 (Strong Buy).
ALKERMES INC (ALKS): Free Stock Analysis
ALEXION PHARMA (ALXN): Free Stock Analysis
ANI PHARMACEUT (ANIP): Free Stock Analysis
QIAGEN NV (QGEN): Free Stock Analysis Report
To read this article on Zacks.com click here.